Dazucorilant

Corcept Therapeutics submitted an NDA to the FDA for relacorilant, a treatment for Cushing's syndrome, following positive trial outcomes. The drug shows symptom improvement without common adverse effects. With a strong financial position and a 61.5% stock return over six months, Corcept aims to make relacorilant a standard treatment.

Dazucorilant, a cortisol modulator, failed to slow ALS progression in a Phase 2 trial, showing no significant difference over placebo. Gastrointestinal side effects were more common with dazucorilant. Five deaths occurred in the placebo group compared to none in the high-dose group. Participants are now in an open-label extension study. Complete results will be presented at a scientific conference next year.

Corcept Therapeutics announced DAZALS Phase 2 trial results for dazucorilant in ALS patients. The study did not meet its primary endpoint but showed fewer deaths in the 300 mg group vs. placebo. An open-label extension study continues, with overall survival assessment in March 2025. Dazucorilant has FDA Fast Track Designation.

Corcept Therapeutics' Phase 2 DAZALS study on dazucorilant for ALS did not meet its primary endpoint of slowing motor skill decline but observed lower mortality in the higher dose group. This finding suggests a potential neuroprotective effect, shifting ALS research focus towards cortisol modulation for extending survival.

Corcept Therapeutics' dazucorilant failed to slow ALS progression in a phase 2 trial, missing primary endpoints and causing more gastrointestinal upset. Despite earlier promise in animal models, the trial's outcome reflects the challenges in ALS treatment development. Corcept plans to continue dazucorilant's development with a long-term study.

Corcept Therapeutics announced results from the DAZALS study, a Phase 2 trial evaluating dazucorilant in ALS patients. The study did not meet its primary endpoint, but showed fewer deaths in the 300 mg arm compared to placebo. An open-label extension study will continue, with overall survival assessed in 2025. Dazucorilant has Fast Track Designation from the FDA.

Corcept Therapeutics announced Phase 2 DAZALS study results for dazucorilant in ALS patients. The study did not meet its primary endpoint on ALSFRS-R improvement but noted fewer deaths in the 300 mg group vs. placebo. An open-label extension study continues, with overall survival assessment due in March 2025. Dazucorilant has FDA Fast Track Designation.

Corcept Therapeutics announced DAZALS study results, a Phase 2 trial for dazucorilant in ALS patients. The trial didn't meet its primary endpoint but noted fewer deaths in the dazucorilant group. An open-label extension study continues, with survival assessment in March 2025. Dazucorilant has FDA Fast Track Designation.